Ozempic does not produce a predictable weekly rate of weight loss. The best evidence reports averages across groups over many months, and individual results vary. In trials included in the current US prescribing information, mean reductions ranged from about 3.8 kilograms after 30 weeks at 0.5 mg to 6.4 kilograms after 40 weeks at 2 mg in adults with type 2 diabetes.
The clearest numbers come from months of follow-up
The May 2026 US Ozempic label reports a 30-week monotherapy trial in which participants lost an average 3.8 kg with 0.5 mg and 4.7 kg with 1 mg, compared with 1.2 kg on placebo. In a separate 40-week trial comparing doses, the mean change was 5.6 kg with 1 mg and 6.4 kg with 2 mg. FDA Ozempic prescribing information, revised May 2026
These are averages, not targets or minimums. Some participants lost more, some less and some may have gained weight. The studies involved adults with type 2 diabetes, and their designs, background medicines and starting weights differed.
In the published SUSTAIN FORTE trial, the treatment-policy analysis found a 6.4 kg mean reduction at 2 mg and 5.6 kg at 1 mg after 40 weeks. The difference in body weight under that analysis did not cross the trial’s conventional threshold for statistical significance. SUSTAIN FORTE trial
Why the first four weeks can mislead
The US label starts Ozempic at 0.25 mg once weekly for four weeks, then increases to 0.5 mg. The purpose of that escalation is to reduce gastrointestinal adverse reactions; 0.25 mg is an initiation step, not the full maintenance range. FDA Ozempic prescribing information
A dramatic early change can include shifts in appetite, fluid, food intake and gastrointestinal symptoms. A quiet first month does not prove the medicine will fail. Either result is a poor reason to change the dose without the prescriber who is managing the treatment.
Ozempic and Wegovy-dose trials are not interchangeable
Ozempic is not labelled by the US Food and Drug Administration for chronic weight management. Its current indications concern type 2 diabetes, cardiovascular risk reduction in certain adults with type 2 diabetes and cardiovascular disease, and kidney outcomes in certain adults with type 2 diabetes and chronic kidney disease. FDA Ozempic prescribing information
The often-quoted 14.9% average reduction at 68 weeks comes from STEP 1, which studied 2.4 mg weekly semaglutide plus lifestyle intervention in adults with overweight or obesity without diabetes. That dose and population correspond to the chronic-weight-management evidence base, not an Ozempic trial. It should not be used as a personal Ozempic forecast. STEP 1 trial in the New England Journal of Medicine
Why individual results vary
- Starting weight, duration of diabetes and other medical conditions.
- The prescribed dose, whether it is tolerated and how consistently it is taken.
- Other medicines, especially those that affect glucose, appetite or body weight.
- Changes in food intake, activity, sleep, illness and fluid balance.
- How long treatment continues and which outcome the clinician is prioritising.
A prescriber may care first about glucose control, cardiovascular or kidney risk, tolerability and safety. Weight is one outcome, not the only measure of whether treatment is appropriate.
Use a trend, not a weekly verdict
If weight monitoring is part of the care plan, use the same scale under similar conditions and review a multi-week trend. Agree in advance with the prescriber when progress, side effects and the treatment goal will be reviewed. Do not chase a trial average by taking more than prescribed or shortening the interval.
Nausea, vomiting, diarrhoea, abdominal pain and constipation are among the common adverse reactions in the label. Persistent vomiting or diarrhoea can lead to dehydration and kidney injury. Severe or persistent abdominal pain, symptoms of a serious allergic reaction, sudden vision changes or other worrying symptoms need prompt medical advice.
Safety questions belong with a clinician
The FDA label carries a boxed warning about thyroid C-cell tumours observed in rodents and states that Ozempic is contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. It also includes warnings about pancreatitis, diabetic retinopathy complications, hypoglycaemia with certain diabetes medicines, gallbladder disease, severe gastrointestinal reactions and aspiration risk around anaesthesia or deep sedation. FDA Ozempic prescribing information
Tell the relevant clinician that you use semaglutide before surgery or a procedure. Discuss pregnancy plans, other medicines and a history of serious gastrointestinal, pancreatic, gallbladder, kidney or eye problems. Do not start, stop or change the dose on the basis of an online weight-loss estimate.
